GA-map® MHI GutHealth

About Pangea Laboratory

Pangea Laboratory is a U.S.-based diagnostic services company founded in 2019, operating a high-complexity clinical lab. It provides end-to-end NGS services from R&D through commercialization, serving as a development and reference lab partner. The company has a growing menu of proprietary non-invasive tests, including an FDA Breakthrough Device-designated assay for bladder cancer, and is expanding into microbiome and infectious disease diagnostics. Its business model combines fee-for-service lab work with the development and launch of its own diagnostic products.

About Genetic Analysis

Genetic Analysis AS is a diagnostic company focused on unlocking the potential of the human microbiome through its proprietary GA-map® technology platform. A key achievement is the commercialization of the world's first CE-marked IVD test for gut dysbiosis in IBS and IBD, which has been used in over 50 clinical trials. The company is strategically expanding its product portfolio with research-use assays like the MHI GutHealth test, developed with Ferring Pharmaceuticals, and pursuing opportunities in companion diagnostics to support pharmaceutical development.

Therapeutic Areas